CagriSema cuts body weight 22.4% versus placebo in 52-week fMRI study
Novo Nordisk also reported liver fat returning below 5% in 23 of 26 STEP-UP participants with elevated baseline liver fat at 72 weeks.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 9 21:31 ETSource: AD HOC NEWS
The wire
- 01At EASD, Novo Nordisk presented a 52-week fMRI study showing 22.4% weight reduction with CagriSema versus placebo, alongside dampened hunger signalling and reduced organ fat.
- 02A separate real-world analysis presented September 29 linked 2 mg semaglutide to lower major adverse cardiovascular event risk than switching to tirzepatide in type 2 diabetes.
- 03The liver fat result is an exploratory post-hoc subgroup analysis of 26 patients; separately, FDA extended review of hemophilia candidate Denecimig over manufacturing site remediation.
From the source
Read at ad-hoc-news.deNovo Nordisk's CagriSema Delivers 22.4% Weight Loss as Liver Data and Pipeline Deals Offset FDA Setb
Fresh clinical readouts are reshaping the investment case for Novo Nordisk, with the Danish drugmaker using this year's European Association for the Study of Diabetes (EASD) annual meeting to showcase data across its obesity and diabetes franchise.
